Cooperative Agreement UH2CA292130
Award Date
9/13/24
Completion Date
8/31/25
Dollars Obligated
$585K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Cooperative Agreement
Place of Performance
Houston, TX 77030, USA
Similar Awards
The federal Project Grant award R01CA299421, totaling $653,819.00, was awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Johns Hopkins University. The goal of this 5-year project (Feb 2025 - Jan 2030) is to develop a highly specific blood-based early detection test for pancreatic cancer, coupled with innovative approaches to leverage imaging, risk factor, and genetic data to more precisely guide the management of high-risk patients. The...
This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...
The National Cancer Institute (NCI) awarded a $737,444 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Hawaii to conduct research aimed at "Uncovering Causal Protein Markers to Characterize Pancreatic Cancer Etiology and Improve Risk Prediction." The project seeks to: 1) identify putative causal protein biomarkers for pancreatic ductal adenocarcinoma (PDAC) risk using novel research methods; 2) functionally characterize...
This federal Cooperative Agreement award, funded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to create a comprehensive 3D atlas depicting the progression of pancreatic cancer precursor lesions to invasive pancreatic ductal adenocarcinoma (PDAC) in individuals with genetic defects in DNA repair genes (BRCA1, BRCA2, PALB2). The $1,035,138 award, with a period of performance from Sep 1, 2024 to Aug 31, 2029, will support...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $432,889 to The Johns Hopkins University to conduct research aimed at advancing cancer screening, diagnostic technologies, and early detection methodologies. The project, titled "Molecular Imaging and Metabolotheranostics of PDAC-Induced Cachexia", will focus on reversing cachexia (severe muscle wasting) induced by pancreatic ductal adenocarcinoma...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Federal Grant Program "Cancer Biology Research" (CFDA 93.396), provides $640,760 to The Leland Stanford Junior University to conduct comprehensive research on the fundamental biological mechanisms underlying pancreatic ductal adenocarcinoma (PDAC) metastasis, organ tropism, and immune evasion. The key products and services to be delivered through this 5-year project include: 1) employing molecular...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $692,491 to the University of Chicago to investigate early epigenetic signatures for common cancers, including prostate, lung, colorectal, and ovarian cancer. The primary goals are to: 1) train and validate individual cancer detection models using samples from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial; 2) develop a multi-cancer...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Sloan-Kettering Institute for Cancer Research provides $263,086 to develop a multiparametric endoscopic ultrasound (MPEUS) imaging system and methodology for improved pancreatic cancer screening and characterization. The goal is to create a non-subjective, quantitative approach for detecting and characterizing pancreatic cancer and precursor lesions in high-risk...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,280,475.00 to The Leland Stanford Junior University to develop a novel approach for early detection of colorectal cancer using cell-free DNA (cfDNA) methylation profiles. The key objectives are to: (1) characterize the early-stage colorectal cancer cfDNA methylome landscape, and (2) develop a machine learning model to detect early-stage colorectal cancer from...
The National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded an $821,797 Project Grant to Early IS Good, Inc. to execute a clinical validation study for their BCDX bladder cancer diagnostic assay. BCDX uses advanced nanotechnology to detect 12 different biomarkers directly from a urine sample, providing a comprehensive, multi-omic, and multiplex approach to bladder cancer detection and recurrence monitoring. The 2-year project aims...